Acadia Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Key Insights
Acadia Pharmaceuticals will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, at 1:30 p.m. Eastern Time.
The company markets the first and only FDA-approved treatments for Parkinson's disease psychosis (search) and Rett syndrome (search), addressing significant unmet needs in neurological and rare diseases.
Acadia's pipeline includes mid- to late-stage programs targeting Alzheimer's disease psychosis (search) and Lewy body dementia psychosis (search), along with earlier-stage programs for underserved patient populations.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced on July 30, 2026, that it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 1:30 p.m. Eastern Time. The event offers investors and industry stakeholders an opportunity to gain insight into the company's strategic direction, commercial performance, and pipeline progress.
Live webcasts of the presentation will be accessible on the company's website, acadia.com, under the investors section. An archived recording will remain available for approximately one month following the presentation.
A Differentiated Neuroscience Portfolio
Acadia Pharmaceuticals has established itself as a focused player in the neurological and rare disease space. The company's commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis (search) and Rett syndrome (search)—two conditions that have historically lacked targeted therapeutic options. Parkinson's disease psychosis represents a significant burden for patients and caregivers, while Rett syndrome is a rare neurodevelopmental disorder with profound impacts on affected individuals and their families.
Pipeline Targeting High-Unmet-Need Indications
Beyond its marketed products, Acadia is advancing a robust and diverse pipeline. The company's mid- to late-stage clinical programs include investigational therapies for Alzheimer's disease psychosis (search) and Lewy body dementia psychosis (search), both of which represent areas of substantial unmet medical need. These neuropsychiatric complications of neurodegenerative diseases are associated with accelerated cognitive decline, increased caregiver burden, and earlier institutionalization.
Earlier-stage programs in Acadia's pipeline address additional underserved patient populations, though specific details regarding these candidates were not disclosed in the announcement.
Corporate Outlook
The fireside chat format at the Canaccord conference is expected to provide a forum for Acadia's management to discuss commercial execution, pipeline milestones, and the company's broader strategy in the neuroscience arena. Investors and analysts will be watching for updates on the progress of late-stage programs and any commentary on market dynamics for the company's approved therapies.